Dr. Annalisa Jenkins is a life sciences thought leader with over 20 years of biopharmaceutical industry experience. Prior to joining PlaqueTec as CEO in November 2017, Dr. Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that was acquired by Ultragenyx in November 2017. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years - including serving as senior vice president and head of global medical affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Dr. Jenkins is a board member of several growing companies, including Ardelyx, Inc., iOX Therapeutics Limited, Thrombolytic Strategies Incorporated, PhESi, Oncimmune, Cocoon Biotech Inc. (Non Executive Chair), Cellmedica (Non-Executive Chair), Vium, Inc. (Executive Chair), and Silence Therapeutics (Non-Executive Chair). She also is a committee member of the Science Board to the U.S. Food & Drug Administration (FDA), and serves on the board of the Center for Talent Innovation in the U.K. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.

Bob Damms MA (Cantab) is an expert in the assessment and development of new products and technologies. He has over 25 years' experience of developing new biomedical technologies through roles in industry, consulting, venture capital and equities research. He has worked across most biomedical subsectors, including biotechnology, pharmaceuticals, medical devices and eHealth, and from university start-ups, SMEs, global corporations and governments. His particular interests include the convergence of technologies in the healthcare sector, translational research, and novel commercialisation models. He is currently seconded to the UKTI's Venture Capital unit.

Karolina has nearly a decade of experience in investing and building life sciences and healthcare companies within the Cambridge Cluster. Currently, she sits on the boards of 5 early-stage companies in Cambridge. She played a pivotal role in securing pre-seed, seed and Series A investments from a stellar syndicate of investors. In 2018, she co-founded and successfully delivered the first life sciences startup accelerator in Cambridge, nurturing a portfolio of 20 early-stage ventures that raised over £68m.

Her career commenced as a scientist at a leading biopharmaceutical company, contributing to the development of a diverse product portfolio for clinics. Karolina holds a PhD in protein folding (diabetes & neurosciences) from the University of Cambridge and conducted postdoctoral research in drug development at AstraZeneca. The majority of her research work focused on peptide pharmaceuticals associated with diabetes type I and II.